Comparison of Neuroleptic Binding Characteristics in Rat Striatum and Renal Cortex

References

• Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature 1979; 277: 93–96
   PubMed Web of Science ®Google Scholar
• Seeman P. Brain dopamine receptors. Pharmacol. Rev. 1980; 32: 229–313
   PubMed Web of Science ®Google Scholar
• Stoof J. C., Kebabian J. W. Opposing roles for D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981; 294: 366–368
   PubMed Web of Science ®Google Scholar
• Onali P., Onalias M. C., Gessa G. L. Selective blockade of dopamine D1 receptors by SCH 23390 discloses striatal dopamine D2 receptors mediating the inhibition of adenylate cyclase in rats. Eur. J. Pharmacol. 1984; 99: 127–128
   PubMedGoogle Scholar
• Jenner P., Elliott P. N.C., Clow A., Reavill C., Marsden C. D. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs. J. Pharm. Pharmacol. 1978; 30: 46–48
   PubMed Web of Science ®Google Scholar
• Hall H., Sällemark M., Jerning E. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol. Toxicol. 1986; 58: 61–70
   PubMedGoogle Scholar
• Iorio L. C, Barnett A, Leitz F. H, Houser V. P., Korduba A. SCH 23390, a potential benzapine antipsychotic with unique interactions on dopaminergic systems. J.Pharm.Exp.Ther. 1983; 226: 462–468
   PubMed Web of Science ®Google Scholar
• Hyttel J. SCH 23390 - the first selective dopamine D1 antagonist. Eur. J. Pharmacol. 1983; 91: 153–154
   PubMed Web of Science ®Google Scholar
• Seeman P., Ulpian C., Grigoriadis D., Pri-Bar I., Buchman O. Conversion of dopamine D-1 reeptors from high to low affinity for dopamine. Biochem. Pharmac. 1985; 34: 151–154
   PubMed Web of Science ®Google Scholar
• Wreggett K. A., Seeman P. Agonist high- and low-affinity states of D2 dopamine receptor in calf brain: Partial conversion by guanine nucleotide. Mol. Pharmacol. 1981; 25: 10–17
   Google Scholar
• Goldberg L. J., Kohli J. D. Peripheral pre- and postsynaptic dopamine receptors: are they different from dopamine receptors in the central nervous system. Commun. Psychopharmacol. 1979; 3: 447–456
   PubMed Web of Science ®Google Scholar
• Lokhandwala M. F., Barrett R. J. Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J. Auton.Pharmac. 1982; 3: 189–215
   Google Scholar
• Willems J. L., Buylaert W. A., Lefebvre R. A., Bogaert M. G. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev. 1985; 37: 165–216
   PubMed Web of Science ®Google Scholar
• Shepperson N. B., Duval N., Massingham R., Langer S. Z. Differential blocking effects of several dopamine receptor antagonists for peripheral pre- and postsynaptic dopamine receptors in the anesthetized dog. J.Pharm.Exp.Ther. 1982; 221: 753–761
   PubMed Web of Science ®Google Scholar
• Hietala J. A., MacDonald E., Scheinin M. Presynaptic dopamine receptors in the pithed rat: characterization with apomorphine and comparison with central dopamine autoreceptors. Acta Pharmacol et Toxicol. 1986; 59: 291–297
   PubMedGoogle Scholar
• Felder R. A., Blecher M., Eisner G. M., Jose P. A. Cortical tubular and glomerular dopamine receptors in the rat kidney. Am. J. Physiol. 1984; 246: F557–568
   PubMed Web of Science ®Google Scholar
• Lowry D. H., Rosebrough N. J., Farr A. R., Randall J. R. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Rosenblatt J. E., Shore D., Wyatt R. J., Pert C. B. Increased renal neuroleptic binding in spontaneously hypertensive rats. Eur. J. Pharmacol. 1980; 67: 317–320
   PubMed Web of Science ®Google Scholar
• McPherson G. Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC. J Pharmac. Methods 1985; 14: 213–228
   PubMedGoogle Scholar
• Munson P. J., Rodbard D. LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem. 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar
• Cheng Y. C., Prusoff W. H. Relationship between the inhibition constant and the concentration which caused 50 % inhibition of an enzymatic reaction. Biochem.Pharmacol. 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Andorn A. C., Maguire M. E. 3H-spiroperidol binding in rat striatum: two high affinity sites of differing selectivities. J.Neurochem. 1980; 35: 1105–1113
   PubMed Web of Science ®Google Scholar
• Howlett D. R., Nahorski S. R. Quantitative assesment of heterogenous 3H-spiperone binding to rat neostriatum and frontal cortex. Life Sci. 1980; 26: 511–517
   PubMedGoogle Scholar
• List S. J., Seeman P. Resolution of dopamine and serotonin receptor components of 3H-spiroperone binding to rat brain regions. Proc. Nat. Acad. Sci. 1981; 78: 2620–2624
   PubMed Web of Science ®Google Scholar
• Lazareno S., Nahorski S. R. Selective labelling of dopamine (D2) receptors in rat striatum by 3H-domperidone but not by 3H-spiperone. Eur.J.Pharmacol. 1982; 81: 273–285
   PubMedGoogle Scholar
• Urwyler S., Coward D. Binding of 3H-spiperone and 3H-(-) -sulpiride to dopamine D-2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands. Naunyn Schmiedeberg's Arch. Pharmac. 1987; 335: 115–122
   Google Scholar
• Creese I., Morrow L., Leff S. E., Sibley D. R., Hamblin M. W. Dopamine receptors in the central nervous system. Int. Rev. Neurobiol. 1982; 23: 255–301
   PubMed Web of Science ®Google Scholar
• Seeman P, Ulpian C., Wreggett K. A., Wells J. W. Dopamine receptor parameters detected by 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem. 1984; 43: 221–235
   PubMed Web of Science ®Google Scholar
• Zahniser N. R., Dubocovich M. L. Comparison of dopamine receptor sites labeled by 3H-S-sulpiride and 3H-spiperone in striatum. J.Pharm.Exp.Ther. 1983; 227: 592–599
   PubMedGoogle Scholar
• Luedtke R. R., Molinoff P. B. Characterization of binding sites for 3H-spiroperidol. Biochem. Pharmacol. 1987; 36: 3255–3264
   PubMedGoogle Scholar
• Ögren S.-O., Hall H., Köhler C., Magnusson O., Lindblom L.-O., Ängeby K., Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the brain. Eur. J. Pharmacol. 1984; 102: 459–474
   PubMed Web of Science ®Google Scholar
• Gerlach J., Korsgaard A., Lund-Larsen A., Noring U., Polvsen U. J. New drugs and perspectives in antipsychotic treatment. Clin. Neuropharmacol. 1984; 7(suppl.1)550–558
   Google Scholar
• Hall H., Ögren S.-O., Florvall L. Effect of lipophilicity of substituted benzamides on the dopaminergic effects in vivo and in vitro. Acta Pharmacol. et Toxicol. 1984; 55: 211–215
   PubMedGoogle Scholar
• Brodde O.-E., Gross G. 3H-spiroperidol labels dopamine receptors in membranes from rabbit mesenteric artery. Naunyn Schmiedeberg's Arch. Pharmacol. 1980; 311: 249–254
   Google Scholar
• Nakajima T., Kuruma I. Characterization with 3H-haloperidol of the dopamine receptor in the ret kidney particulate preparation. J Japan. Pharmacol. 1980; 30: 891–898
   PubMedGoogle Scholar
• Goldstein A., Barrett R. W. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol. Pharmacol. 1987; 31: 603–609
   PubMedGoogle Scholar
• Schmidt M., Imbs J. L., Giesen E. M., Schwartz J. Blockade of dopamine receptors in the renal vasculature by isomers of flupenthixol and sulpiride. J. Cardiovascular Pharmacol. 1983; 5: 86–89
   PubMedGoogle Scholar
• Arbilla S., Langer S. Z. Stereoselectivity of presynaptic autoreceptors modulating dopamine release. Eur. J. Pharmacol. 1981; 76: 345–351
   PubMedGoogle Scholar
• Brown R. A., O'Connor S. E. Stereoselctive antagonism of prejunctional dopamine receptors in the rabbit ear artery by sulpiride. Br J Pharamacol. 1981; 73: 189P–190P
   Google Scholar
• Goldberg L. I., Kohli J. D., Listinsky J. J., McDermed J. D. Structure-activity relationships of the pre- and postsynaptic dopamine receptors mediating vasodilation. Catecholamines: Basic and Clinical Frontiers, E. Usdin, I. J. Kopin, J. Barchas. Pergamon Press, New York 1979; 447–449
   Google Scholar
• Sabouni M. H., Alkadhi K. A., Lokhandwala M. F. Pharmacologcal characterization of dopamine receptors in the stellate ganglia with selective DA-1 and DA-2 receptor agonists and antagonists. J. Pharmacol. Exp. Ther. 1986; 236: 65–70
   PubMed Web of Science ®Google Scholar
• Sabouni M. H., Alkadhi K. A., Lokhandwala M. F. Effects of dopamine receptor activation on ganglionic transmission and cyclic AMP levels in the stellate ganglia and renal arteries of the dog. J. Pharmacol. Exp. Ther. 1987; 240: 93–98
   PubMedGoogle Scholar
• Gonzales M. C., Artalejo A. R., Montiel C., Hervas P. P., Garcia A. G. Characterization of a dopaminergic receptor that modulates adrenomedullary catecholamine release. J. Neurochem. 1986; 47: 382–388
   PubMed Web of Science ®Google Scholar
• Williams B. C. Dopamine in the kidney. The neurobiology of dopamine systems, W. Winlow, R. Markstein. Wheaton & Co, ExeterEngland 1986; 385–401
   Google Scholar